15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $236M | -$5M | 83.3% | 9.9% | -16.3% | -1.4% | $68M | $48M | $185M |
| 2024 | $160M | -$69M | 60.6% | -31.5% | 141.1% | -31.4% | -$41M | $39M | $52M |
| 2023 | $195M | -$52M | 61.9% | -23.8% | 169.7% | -21.5% | -$23M | $35M | $43M |
| 2022 | $292M | -$94M | 70.7% | -27.6% | -1801.1% | -26.5% | -$73M | $66M | $90M |
| 2021 | $212M | -$282M | 28.8% | -125.0% | -381.0% | -53.3% | -$253M | $98M | $150M |
| 2020 | $295M | -$385M | -0.6% | -128.2% | -157.5% | -59.7% | -$111M | $96M | $229M |
| 2019 | $335M | -$280M | 56.6% | -85.5% | -71.2% | -36.3% | -$264M | $76M | $147M |
| 2018 | $208M | -$144M | 96.3% | -85.8% | -22.6% | -14.4% | -$99M | — | $105M |
| 2017 | $181M | -$74M | 0.0% | -42.3% | -60.1% | -20.2% | -$58M | — | $70M |
| 2016 | $2M | -$136M | 0.0% | -8889.9% | -199.3% | -45.2% | $55M | — | $187M |
| 2015 | — | -$61M | — | — | -46.3% | -42.5% | — | — | $50M |
| 2014 | — | -$37M | — | — | -35.6% | -33.4% | — | — | $33M |
| 2014 | — | -$73M | — | — | -56.9% | -54.3% | — | — | $126M |
| 2013 | — | -$13M | — | — | 10.4% | -38.0% | — | — | $21M |
| 2012 | — | -$8M | — | — | 13.8% | — | — | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $49M | -$9M | 78.8% | -12.9% | -35.6% | -2.5% | $2M | $50M | $156M |
| Mar '26 | $54M | -$9M | 77.0% | -8.8% | -33.1% | -2.5% | -$21M | $49M | $163M |
| Dec '25 | $58M | -$12M | 78.2% | -14.8% | -37.5% | -3.3% | $31M | $48M | $185M |
| Sep '25 | $59M | $540000 | 84.0% | 7.6% | 1.3% | 0.1% | $28M | $48M | $166M |
| Jun '25 | $62M | $247000 | 84.1% | 22.6% | 0.8% | 0.1% | $22M | $47M | $137M |
| Mar '25 | $57M | $6M | 86.7% | 23.6% | 24.9% | 2.0% | -$14M | $47M | $113M |
| Dec '24 | $46M | -$23M | 56.2% | -30.8% | 46.4% | -10.3% | -$4M | $39M | $52M |
| Sep '24 | $37M | -$20M | 62.2% | -33.4% | 39.8% | -9.7% | -$7M | $38M | $34M |
| Jun '24 | $44M | -$9M | 60.9% | -20.0% | 25.4% | -3.9% | -$10M | $38M | $39M |
| Mar '24 | $33M | -$18M | 64.4% | -45.8% | 66.0% | -8.0% | -$19M | $30M | $42M |
| Dec '23 | $56M | $614000 | 66.8% | 2.4% | -2.0% | 0.3% | -$2M | $35M | $43M |
| Sep '23 | $42M | -$14M | 57.2% | -31.0% | 36.8% | -6.2% | -$7M | $43M | $47M |
| Jun '23 | $56M | -$11M | 69.3% | -16.0% | 41.7% | -4.4% | $4M | $42M | $54M |
| Mar '23 | $40M | -$27M | 49.5% | -64.0% | 140.5% | -9.6% | -$18M | $50M | $57M |
| Dec '22 | $56M | -$6M | 106.1% | -8.7% | -116.1% | -1.7% | -$55M | $66M | $90M |
| Sep '22 | $49M | -$54M | 21.4% | -103.5% | -655.0% | -12.2% | $34M | $66M | $145M |
| Jun '22 | $126M | $29M | 85.3% | 27.0% | 50.0% | 5.6% | -$31M | $98M | $144M |
| Mar '22 | $62M | -$62M | 49.2% | -94.8% | -276.4% | -11.5% | -$22M | — | $175M |
| Dec '21 | $60M | -$71M | 15.5% | -111.0% | -95.5% | -13.4% | -$63M | $98M | $150M |
| Sep '21 | $49M | -$60M | 67.3% | -112.6% | -43.4% | -9.9% | -$56M | $97M | $207M |
How the market has priced AKBA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Akebia Therapeutics, Inc.'s revenue has declined 4.3% per year. These are computed facts, not advice.
As of FY2025, Akebia Therapeutics, Inc. reported $48M of total debt against $185M of cash.
In FY2025, gross margin was 83.3%, operating margin 9.9%, and net margin -2.2%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.